Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Comparing functional and genomic-based precision medicine in blood cancer patients

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB
[thumbnail of Supporting Information]
Preview
PDF (Supporting Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
658kB

Item Type:Article
Title:Comparing functional and genomic-based precision medicine in blood cancer patients
Creators Name:Kazianka, L., Pichler, A., Agreiter, C., Rohrbeck, J., Kornauth, C., Porpaczy, E., Sillaber, C., Sperr, W.R., Gleixner, K.V., Hauswirth, A., Jäger, U., Valent, P., Jonak, C., Porkert, S., Exner, R., Willenbacher, W., Wolf, D., Neumeister, P., Prochazka, K., Deutsch, A., Greil, R., Schmitt, C., Ristl, R., Mayerhoefer, M., Simonitsch-Klupp, I., Pemovska, T. and Staber, P.B.
Abstract:Tumor-agnostic precision medicine (PM) strategies promise to support treatment decisions in relapsed/refractory blood cancer patients. Genomic-based PM (gPM) and drug screening-based functional PM (fPM) currently represent the most prominent PM methodologies. In this study, we report the feasibility analysis of the first 55 patients enrolled in the multicentric, randomized controlled EXALT-2 trial (NCT04470947) comparing treatment recommendations of gPM, fPM, and physicians' choice (PC) head to head. In 54 patients (98%), the diagnostic workflow was successfully implemented, resulting in treatment recommendations for 42 patients (76%), of whom 29 (69%) received the suggested individualized treatments. Actionable targets were identified in 65% by gPM and 80% by fPM (64% microscopy-based, 86% flow cytometry-based fPM). The median time to report was shorter for fPM than for gPM testing. The two strategies revealed overlapping drug targets in 60% of cases. Both, gPM and fPM can efficiently be integrated into the clinical routine to guide therapy decisions for the majority of patients.
Source:HemaSphere
ISSN:2572-9241
Publisher:Wiley
Volume:9
Number:4
Page Range:e70129
Date:April 2025
Official Publication:https://doi.org/10.1002/hem3.70129
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library